Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHKA | P35790 | 3/20 | 0.38 |
| ▸ | APEX1 | P27695 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | TERT | O14746 | 1/20 | 0.33 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21955684 | 0.92 | APEX1 (0.42) | CHKAAPEX1TERTKCNN3 | |
| SCHEMBL4359812 | 0.92 | — | — | |
| SCHEMBL19089065 | 0.92 | APEX1 (0.42) | CHKAAPEX1TERTKCNN3 | |
| SCHEMBL30547267 | 0.83 | CHKA (0.32) | CHKAACHE | |
| SCHEMBL29894137 | 0.83 | CHKA (0.32) | CHKAACHE | |
| SCHEMBL30945595 | 0.83 | CHKA (0.32) | CHKAACHE | |
| Hydrogen Sulfide SCHEMBL23044042 | 0.80 | CHKA (0.31) | CHKAACHE | |
| SCHEMBL30050918 | 0.79 | APEX1 (0.60) | CHKAAPEX1TERT | |
| SCHEMBL29386754 | 0.79 | APEX1 (0.60) | CHKAAPEX1TERT | |
| Ammonia Solution, Strong SCHEMBL3063865 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146768-A1 | PROCESSES FOR PREPARING POLYMERS USING ALPHA,OMEGA-DIFUNCTIONAL ALDARAMIDES | E. I. DU PONT DE NEMOURS AND COMPANY | 2008-06-19 | — | — | US | disclosed |
| EP-1858955-A1 | PROCESSES USING ALPHA, OMEGA-DIFUNCTIONAL ALDARAMIDES AS MONOMERS AND CROSSLINKERS | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2007-11-28 | — | — | EP | disclosed |
| US-20060264672-A1 | Processes using alpha, omega-difunctional aldaramides as monomers and crosslinkers | E. I. DU PONT DE NEMOURS AND COMPANY | 2006-11-23 | — | — | US | disclosed |
| WO-2006091901-A1 | PROCESSES USING ALPHA, OMEGA-DIFUNCTIONAL ALDARAMIDES AS MONOMERS AND CROSSLINKERS | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264672-A1 | Processes using alpha, omega-difunctional aldaramides as monomers and crosslinkers | ALOX5, GSTO1, FASN | CHKA 405/4885APEX1 624/4885ACHE 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.